The Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA-1) is a latent viral protein that is expressed in all EBV-immortalized lymphocytes and plays an essential role in immortalization by EBV. EBNA-1 protein is required for replication and maintenance of the episomal viral genome in latently infected, immortalized cells. Given the essential function of EBNA-1 in immortalization, we have examined the effect of EBNA-1 antisense oligodeoxynucleotides on expression of EBNA-1 protein and proliferation in EBV-immortalized lymphoblastoid cells. We have shown that exposure to unmodified antisense oligodeoxynucleotide of codons 6 through 10 of EBNA-1 partially suppressed EBNA-1 protein expression in EBV-immortalized lymphoblastoid cells relative to untreated PSTEIN-BARR VIRUS (EBV), a B-lymphotropic human herpes virus, is causally associated with several human B-cell malignancies, including endemic Burkitt's lymphoma, acquired immunodeficiency syndrome (AIDS)-associated lymphoma, and lymphoproliferative disease in transplant recipients.'.' The biologic activity of EBV that implicates this virus in the etiology of these tumors is its ability to immortalize B lymphocytes. EBV infection of B lymphocytes in vitro or in vivo results in transformation to immortalized lymphoblastoid cells that are capable of proliferating indefinitely and harbor the virus in a latent Latently infected immortalized B cells are characterized by multiple copies of the viral genome present as extrachromosomal episomes that replicate synchronously with cell division and partition to daughter Although the EBV genome encodes about 100 genes, viral gene expression is tightly restricted to only a few genes in latently infected immortalized cells, including the six EBV nuclear antigen genes (EBNA-I, -2, -3a, -3b, -3c. and LP). two latent membrane protein genes (LMP-1 and LMP-2), and the EBER genes that encode two small polymerase I11 transcripts.' Considerable evidence indicates that some of these latently expressed viral genes are involved in the immortalization of host c e k 5
enhancement of viral transcription, are mediated by DNA binding of EBNA-I to specific sites within the latent origin of replication of the episomal viral genome, ~r i P . '~. ' ' Thus, EBNA-1 expression is essential to the immortalizing actions of EBV. Although there are cell-type-dependent differences in latent EBV gene expression, EBNA-l is expressed in all EBV-infected B cells, including endemic Burkitt's lymphoma and immortalized lymphoblastoid cell line^.'^.'' The other latent viral genes (EBNA-2, -3a, -3b, and -3c, and LMP-1 and -2) are downregulated and not expressed in Burkitt's lymphoma cells in vivo and in early passage in vitro.'"'' EBNA-1, in contrast, is consistently expressed in Burkitt's lymphoma cells, confirming the essential role of this viral product in maintenance of latent viral infection.'"'' Given the essential functions of EBNA-l in immortalization, suppression of EBNA-l expression would be expected to disrupt the immortalization process by inhibiting replication of the viral episome with eventual loss of the viral genome. It is also possible that suppression of EBNA-1 expression may result in altered transcription of other viral genes and further disrupt the immortalized phenotype.
To determine whether EBNA-1 antisense oligodeoxynucleotides can suppress EBNA-I protein expression and disrupt immortalization, we tested the effects of antisense oligodeoxynucleotides of EBNA-1 for their effect on cellular proliferation and expression of EBNA-I protein.
EBNA-1 ANTISENSE: EFFECTS ON IMMORTALIZED B CELLS 583 Imrnunoblotting. Cells were plated at a concentration of 2 X 10' cells/mL in 150 pL of RPMI 1640 plus 5% FCS. At 48-hour intervals, 50% of the medium was replaced with fresh medium. Oligodeoxynucleotides were added at at final concentration of 40 pmoVL at 0, 48, 96, and 1 4 4 hours just after the addition of fresh medium. Cells were harvested on day 2 or 7 of culture for immunoblottting. For each immunoblotting experiment, exactly 8 X IO4 viable cells were used for each condition. To determine the concentration of viable cells, cells were suspended in trypan blue, and at least 400 cells that excluded trypan blue were counted using a hemocytometer chamber. Cells were washed once in phosphate-buffered saline and solubilized in 20 p L of sample buffer (50 mmoVL Tris-HC1, pH 6.8, 4% wt/vol sodium dodecyl sulfate, 2% vol/vol 2-mercaptoethanol, 10% glycerol, 0.01% bromophenol blue) at a concentration of 4 X IO6 cells/mL. The samples were sonicated, boiled for 3 minutes, and immediately loaded on a discontinuous polyacrylamide gel consisting of a 3% stacking gel and a 7.5% resolving gel. Prestained low molecular weight markers (Bio-Rad, Richmond, CA) were loaded in parallel. After electrophoretic resolution, the protein samples were transferred electrophoretically to nitrocellulose paper (500 mAmp for at least 5 hours at 4°C). The immunoblotting procedure was then performed according to the manufacturer's protocol for the enhanced chemiluminescence (ECL) Western Blotting System (Amersham, Arlington Heights, IL). For primary antibody, EBV-seropositive human sera that was previously characterized as containing high titer of antibody to EBNA-l was used at a dilution of 1:lOO (provided by James Jones, National Jewish Center, Denver, CO). For secondary antibody, peroxidase-linked antihuman Ig from sheep (Amersham) was used at a dilution of 1:4,OOO. The blots were blocked, incubated with primary and secondary antibody, washed, exposed to the chemiluminescence reagents, and exposed to Kodak XAR film (Eastman Kodak, Rochester, NY), as described in the manufacturer's protocol.
RESULTS

Effect of EBNA-I antisense oligodeoxynucleotides on proliferation of EBV-immortalized cells.
Initial experiments were undertaken to determine whether EBNA-1 antisense oligodeoxynucleotides inhibit proliferation of EBV-immortalized cells. The effect of two different antisense oligodeoxynucleotides, AS1 and AS2 (antisense to nucleotides + l to + l 5 and + l 6 to +30, respectively), on proliferation of two EBV-positive cell lines (X50-7 and 11-23) was tested.
EBV-positive cells were exposed to AS1 or AS2 at concentrations of 10, 20, and 40 pmoVL for 7 days and assayed for proliferation by ['Hlthymidine incorporation, as described in Materials and Methods. Both AS1 and AS2 inhibited proliferation of both EBV-positive cell lines in a dose-dependent manner relative to untreated cells (Table 2) . At each concentration of oligodeoxynucleotide, AS2 was a more potent inhibitor of proliferation than AS1 in both cell lines. Thus, subsequent experiments were conducted using AS2.
Because oligodeoxynucleotides have been reported to nonspecifically inhibit ['Hlthymidine incorporation into cellular DNA by increasing intracellular pools of competing cold thymidine,''.'' additional studies were performed to determine whether the antiproliferative effect of AS2 was a sequence-specific or nonspecific effect of oligodeoxynucleotide. In initial experiments, EBV-positive cells (X50-7 and LS) and EBV-negative cells (U937) were exposed to anti- sense AS2 or scrambled antisense SASl oligodeoxynucleotide (10 pmol/L) for 30 hours. After this short exposure to oligodeoxynucleotides, [3H]thymidine incorporation was suppressed by 25% to 60% relative to untreated cells, but for each cell line there was no significant difference in ['HIincorporation between antisense AS2-treated and scrambled antisense SASl-treated cells (data not shown). Because EBNA-1 is a stable, constitutively expressed protein in EBVimmortalized cells, we postulated that prolonged exposure to oligodeoxynucleotide may be necessary for suppression of EBNA-1 protein and inhibition of proliferation. Therefore, in all subsequent experiments, cells were cultured with oligodeoxynucleotides for 7 days.
Three EBV-positive cell lines (LS, X50-7, and 11-23) and two EBV-negative cell lines (BJAB and U937) were exposed to EBNA 1 antisense, AS2, or the scrambled sequence, SAS1, at a concentration of 10 pmol/L for 7 days, and [3H]thymidine incorporation was measured during the last 16 hours of culture. The scrambled oligodeoxynucleotide inhibited ['Hlthymidine uptake relative to untreated cells by 35% to 65% in all five cell lines. In the three EBV-positive cell lines, EBNA-1 antisense, AS2, significantly inhibited proliferation by 55% to 65% relative to the control scrambled oligodeoxynucleotide, SAS 1 (Fig 1) . In contrast to the differential effect of AS2 and SASl on ['Hlthymidine uptake in EBV-positive cells, there was no significant difference between the antiproliferative effects of EBNA-l antisense and the control scrambled sequence in the two EBV-negative cell lines, BJAB and U937 (Fig 1) . Thus, a significant inhibitory effect of EBNA-l antisense AS2 relative to the scrambled sequence SASl on ['Hlthymidine incorporation was observed only in the EBV-positive cell lines. These observations suggest that the antiproliferative effect of prolonged exposure to EBNA-1 antisense in EBV-positive cells was, in part, sequence-specific, and not merely a nonspecific effect, and, furthermore, implicate involvement of a viral product in the antiproliferative effect of EBNA-l antisense.
To corroborate the findings of an EBV-specific effect of EBNA-I antisense on cellular proliferation, a second oligodeoxynucleotide, SAS2, representing a different random scrambling of EBNA-1 antisense. was tested for its effect on [3H]thymidine uptake relative to AS2 and SASl in EBVpositive and EBV-negative cell lines. The EBNA-1 antisense oligodeoxynucleotide, AS2, significantly suppressed ['HIthymidine uptake by at least 50% relative to both scrambled oligodeoxynucelotides in the two EBV-positive lines, X50-7 and 11-23 (Fig 2) . In contrast, there was no significant difference between the effect of AS2 and either scrambled oligodeoxynucleotide on [3H]thymidine incorporation in the two EBV-negative lines, U937 and Louckes (Fig 2) . Because two of the three EBV-negative lines tested in these experiments are B-cell lines (BJAB and Louckes), the effect of EBNA-l antisense on proliferation was not simply a B-cellspecific effect.
To determine whether EBNA-1 antisense oligodeoxynucleotide suppresses EBNA-1 protein expression, immunoblotting for EBNA-l was performed using EBV-positive cells exposed to EBNA-1 antisense, AS2, or the scrambled sequences. Cell lysates of exactly 8 X lo4 viable cells were prepared from EBV-positive cell lines after exposure to EBNA-l antisense, AS2, or the scrambled sequence, SAS1, at a concentration of 40 pmol/L for 30 hours or 7 days, and immunoblotting for EBNA-l protein was performed using high titer anti-EBNA-l human serum. After exposure of X50-7 cells to antisense AS2 for 30 hours, there was no detectable suppression of EBNA-1 expression compared with untreated or scrambled oligodeoxynucoletide-treated cells (data not shown). However, after 7 days of exposure to antisense AS2, the amount of EBNA-I protein in cells from three different EBV-positive cell lines exposed to the SASl for each cell line is as follows: X50-7, P < .Owl; 11-23, P = .007; U937, P = .66; Lou, P = .56. The Pvalue for the mean difference between AS2 and SAS2 for each cell line is as follows: X50-7, P < .0001; 11-23, P < .0015; U937, P = .14; Lou, P = .39. The P value for the mean difference between SASl and SAS2 was greater then .05 for all cell lines. antisense oligodeoxynucleotide was substantially decreased compared with cells exposed to scrambled sequence (Fig  3) . Densitometric analysis of the EBNA-I band indicated a reduction of EBNA-I protein in antisense-treated cells of 50% in X50-7 cells, 80% in LS cells, and 85% in 11-23 cells. In contrast, densitometry of an unidentified protein band visible on prolonged exposure of the autoradiograph showed no substantial differences (< 10%) between the EBNA-I -treated cells and the scrambled antisense-treated cells. The finding of a specific decrease (at least 50%) in EBNA-I expression in antisense-treated cells relative to scrambled antisense-treated cells was consistent and reproducible in three separate experiments. In each of these experiments, EBNA-I protein levels were decreased but remained detectable after exposure to EBNA-I antisense, indicating partial rather than complete suppression of protein by unmodified antisense oligodeoxynucleotide. Similar results were obtained when AS2 was compared with the second scrambled antisense sequence, SAS2, in the EBV-positive 1 1-23 cell line (data not shown). The suppression of EBNA-1 protein expression by EBNA-I antisense relative to the scrambled sequence is not simply caused by an artifactual increase in EBNA-I protein in the presence of the scrambled sequence. The scrambled sequence, SAS 1. had minimal effect on EBNA-I protein expression in all three EBV-positive cell lines compared with untreated control cells (Fig 4) .
DISCUSSION
EBNA-1 protein is required for replication of the episomal form of the EBV genome in latently infected cells."'" Furthermore, EBNA-l is the only viral protein that is expressed in tumor cells of EBV-positive Burkitt's lymphoma cells."'"" This latter observation. in conjunction with the known function of EBNA-I in episomal replication, indicates the essential role of this viral product in the maintenance of latent viral infection. Suppression of EBNA-1 protein expression theoretically should lead to loss of viral DNA over successive cell divisions, thereby disrupting latent infection and affecting the immortalized or transformed phenotype. Thus, EBNA-I represents a reasonable target for suppression by antisense oligodeoxynucleotide.
We have shown that unmodified EBNA-I antisense to codons For personal use only. on August 30, 2017. by guest www.bloodjournal.org From sure to EBNA-1 antisense neither suppressed protein expression nor inhibited proliferation relative to scrambled oligodeoxynucleotide-treated cells. These findings suggest that EBNA-1 antisense oligodeoxynucleotide specifically caused suppression of EBNA-1 protein expression that was associated with inhibition of cellular proliferation.
The mechanism by which suppression of EBNA-1 protein expression caused inhibition of proliferation is unknown. Given the essential role of EBNA-I in replication of the viral genome in latent infection, it is possible that viral DNA is lost from a subpopulation of daughter cells over the course of several cell divisions, ultimately reversing the immortalized state of those cells with resultant cessation of proliferation. A second mechanism may derive from the effect of EBNA-l on transcription of latent viral genes. EBNA-l binding sequences within the oriP of the EBV genome are functional enhancer elements, and, in the presence of EBNA-1, enhance transcription from the U1 rightward promoter of the viral g e n~m e .~.~. " Thus, suppression of EBNA-l may also affect the regulation of transcription of other latent viral genes that may be directly involved in immortalization. Although we were using high titer EBNA-l -specific antisera for protein detection in these experiments, we were able to detect EBNA-2 with prolonged exposure of the autoradiographs, and there was no evidence that EBNA-2 levels were substantially affected by EBNA-1 antisense. Elucidation of the mechanism by which EBNA-1 suppresses proliferation of EBV-immortalized cells remains to be explored. This is the first report of the effective use of antisense oligodeoxynucleotides of latent EBV genes to suppress viral protein expression and alter proliferation of EBV-immortalized cells. By using modified, nuclease-resistant oligodeoxynucleotides with greater stability, it may be possible to achieve a more complete suppresion of EBNA-1 protein expression at lower concentrations of DNA. Based on the essential function of EBNA-l in replication of the latent viral episome, suppression of this viral protein would be predicted to have an impact on the immortalized state. Although the exact function of other latent viral products is not known, considerable evidence now indicates that most are involved in the immortalization p r o~e s s .~
The effect of antisense oligodeoxynucleotides of the other EBNAs (EBNA-2, -3a, -3b, -3c, -LP) or the LMPs (LMP-I and -2) on cell proliferation and phenotype would be of great interest.
These studies corroborate the known essential biologic function of EBNA-l in the immortalization process and maintenance of latent viral infection. Furthermore, the use of EBNA-1 antisense may potentially provide a novel therapeutic strategy for the treatment of EBV-positive tumors. Recently, phase I studies have been undertaken using systemic antisense oligodeoxynucleotides in humans." The preliminary findings from these studies indicate that antisense DNA can be administered by continuous infusion without major toxicities. Furthermore, adequate bioavailability can be achieved. Because EBNA-l is expressed in all EBVinfected neoplastic cells and derives from a sequence that does not share significant homology with known mammalian genes, EBNA-1 represents an ideal target for antisense therapy of EBV-positive human tumors. In addition to the therapeutic implications of antisense suppresion of EBNA-I, the use of antisense to EBNA-l or other latent viral genes may provide further insight into the molecular mechanisms of immortalization and neoplastic transformation by EBV.
